BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/17/2026 2:05:36 AM | Browse: 1 | Download: 0
Publication Name World Journal of Clinical Oncology
Manuscript ID 124935
Country China
Received
2026-06-30 08:44
Peer-Review Started
2026-06-30 08:44
First Decision by Editorial Office Director
Return for Revision
2026-07-17 03:11
Revised
2026-08-14 05:42
Publication Fee Transferred
Editorial Processing by Scientific Editor
2026-10-22 03:01
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director
2026-10-22 09:06
Articles in Press
2026-10-22 09:06
Edit the Manuscript by Language Editor
Typeset the Manuscript
2026-10-29 02:08
Publish the Manuscript Online
2026-11-17 02:05
ISSN 2218-4333 (online)
Open Access This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Copyright ©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Basic Study
Article Title HN1 L promotes colorectal cancer proliferation and migration by inhibiting the Hippo pathway
Manuscript Source Unsolicited Manuscript
All Author List Da Kang, Ling-Xin Zeng, Rong-Xin Zhang, Wen-Juan Ma, Rong Yang and Xin Wang
ORCID
Author(s) ORCID Number
Rong-Xin Zhang http://orcid.org/0000-0001-5498-0428
Wen-Juan Ma http://orcid.org/0000-0001-9942-1005
Rong Yang http://orcid.org/0000-0003-4801-1326
Xin Wang http://orcid.org/0009-0000-7565-6547
Funding Agency and Grant Number
Funding Agency Grant Number
2020 Annual Open Research Fund of the Sixth Affiliated Hospital of Guangzhou Medical University No. 202011-103 and No. 202301-314
2022 Special Fund of Qingyuan People’s Hospital No. QYRYCRC2023015
Corresponding Author Xin Wang, MD, Professor, Department of Oncology, The Affiliated Qingyuan Hospital(Qingyuan People's Hospital), Guangzhou Medical University, No.35, Yinquan North Road, Qingcheng District, Qingyuan 511518, Guangdong Province, China. xinwang@gzhmu.edu.cn
Key Words Colorectal cancer; HN1 L; Hippo pathway; Adjuvant therapy; Prognosis
Core Tip This study identifies HN1 L as an oncogenic regulator in colorectal cancer (CRC). Integrated transcriptomic, cellular, xenograft, and clinical analyses demonstrate that HN1 L enhances CRC proliferation and migration by inhibiting Hippo pathway activity, primarily through reduced MOB1 and YAP phosphorylation. Clinically, high HN1 L expression was associated with poorer five-year overall survival, while an exploratory interaction analysis suggested a possible difference in adjuvant chemotherapy benefit according to HN1 L expression. These findings suggest that HN1 L may function as a chemotherapy-response indicator and a potential therapeutic target in CRC.
Publish Date 2026-11-17 02:05
Citation

Kang D, Zeng LX, Zhang RX, Ma WJ, Yang R, Wang X. HN1 L promotes colorectal cancer proliferation and migration by inhibiting the Hippo pathway. World J Clin Oncol 2026; 17(11): 124935

URL https://www.wjgnet.com/2218-4333/full/v17/i11/124935.htm
DOI https://doi.org/10.5306/wjco.124935
Full Article (PDF) WJCO-17-124935-with-cover.pdf